New CEOs Need Digit...
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$50.60 -1.34 | -2.58%
06/19/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 2.57B | 2.79B | 2.89B | 2.63B |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 197.99M | -375.74M | -348.88M | -356.46M |
| (Increase) Decrease in Inventories | -349.92M | -200.79M | -161.19M | -75.27M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 117.48M | 428.94M | -4.45M | 203.64M |
| (Decrease) Increase In Other Current Liabilities | 317.59M | 411.36M | -65.67M | 275.36M |
| (Increase) Decrease In Other Working Capital | 23.24M | -29.48M | -29.73M | 48.60M |
| Other Non-Cash Items | 205.24M | 263.32M | 346.92M | 253.32M |
| Net Cash From Continuing Operations | 3.19B | 3.64B | 2.83B | 3.08B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 3.19B | 3.64B | 2.83B | 3.08B |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 572.52M | 9.44B | 3.72B | 1.88B |
| Purchases of Property, Plant & Equipment | -397.05M | -131.90M | -61.88M | -230.06M |
| Acquisitions | -10.75B | -588.61M | -91.00M | -1.25B |
| Purchases of Short-Term Investments | -1.24B | -5.13B | -5.50B | -2.61B |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -11.85B | 3.59B | -1.94B | -2.22B |
| Issuance of Debt | 0.00 | 4.66B | 2.96B | 400.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 466.28M | 211.74M | 376.65M | 222.73M |
| Repayment of Long-Term Debt | 0.00 | -651.55M | -868.41M | -311.10M |
| Repurchase of Capital Stock | -667.04M | -2.38B | -4.02B | -998.50M |
| Payment of Cash Dividends | 130.60M | -115.04M | 0.00 | 0.00 |
| Other Financing Charges, Net | 633.50M | 40.85M | 213.14M | -364.57M |
| Net Cash From Financing Activities | 563.35M | 1.76B | -1.34B | -1.05B |
| Effect of Exchange Rate Changes | 7.91M | -16.53M | 77.47M | 940.00K |
| Net Change in Cash & Cash Equivalents | -8.08B | 8.98B | -365.08M | -186.34M |
Portfolios with GILD
- Portfolio NameUser Type
- UserDC
- ContributorMost-Active Stocks for the ...
- ProHighbridge Capital Management
- ProSteven Cohen - SAC Capital
- ProJohn Griffin - Blue Ridge C...
- UserMike Fatah's Mega Stock Por...
- UserRenzo's portfolio
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 23
- UserBender
Latest GILD Headlines from TheStreet
- Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 06.17.13 | 05:06 pm
- Biotech Stock Mailbag: Exact Sciences, Questcor, Biotech M&A, Celsion 06.14.13 | 07:06 am
- Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales 06.11.13 | 09:06 am
- Winners And Losers in CLL at ASCO '13 06.10.13 | 07:06 am
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 06.07.13 | 05:06 pm
- Cramer: The Market Welcomes the Jobs Number 06.07.13 | 12:06 pm
- Gilead Sciences Inc Stock Buy Recommendation Reiterated (GILD) 06.07.13 | 10:06 am
- June 14th Options Now Available For Gilead Sciences 06.06.13 | 10:06 am
- CELG, AMGN, GILD, JNJ And PFE, Pushing Drugs Industry Downward 06.04.13 | 01:06 pm
- Cramer's 'Mad Money' Recap: Out With the New 06.03.13 | 08:06 pm
Press Releases for GILD
- Gilead Sciences To Present At The Wells Fargo Securities 2013 Healthcare Conference On Tuesday, June 18 - Business Wire 06.17.13 | 04:06 pm
- Gilead Announces Interim Phase 2 Data For Idelalisib Showing Response In Refractory Indolent Non-Hodgkin’s Lymphoma - Business Wire 06.17.13 | 04:06 am
- Critical Alerts For Nike, Gilead Sciences, HollyFrontier, Brown-Forman, And IMAX Released By InvestorsObserver - PR Newswire 06.06.13 | 09:06 am
- Gilead Announces Update On Phase 3 Study Of Oral Fixed-Dose Combination Of Sofosbuvir And Ledipasvir For Genotype 1 Hepatitis C Patients - Business Wire 03.26.13 | 08:03 am
- European CHMP Adopts Positive Opinion For Stribild®, A Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen For The Treatment Of HIV-1 Infection - Business Wire 03.22.13 | 08:03 am
- Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes - Business Wire 03.10.13 | 02:03 pm
- Gilead Announces Full 24-Week Phase 2 Results For Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) - Business Wire 03.05.13 | 12:03 pm
- Gilead Sciences To Present At The Cowen & Company 33rd Annual Health Care Conference On Monday, March 4 - Business Wire 03.01.13 | 04:03 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.25.13 | 04:02 pm
- Gilead And Teva Reach Settlement Agreement In Viread® Patent Litigation - Business Wire 02.19.13 | 11:02 pm
Partner Headlines for GILD
- Amgen In Focus - Seeking Alpha 06.19.13 | 09:06 am
- Market Close Report: NASDAQ Composite index closes at 3,452.13 up 28.57 points - NASDAQ 06.17.13 | 08:06 pm
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- 3 Impressive Biotech ETFs Crushing the Market - ETF News And Commentary - Zacks 06.11.13 | 03:06 pm
- Big Cap 20 Outperforming S&P 500, IBD 50 Too - Investor's Business Daily 06.10.13 | 06:06 pm
- Priority Review for Gilead Drug - Analyst Blog - Zacks 06.10.13 | 02:06 pm
- Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for June 05, 2013 - NASDAQ 06.04.13 | 01:06 pm
- Stocks Rebound To End Higher; GII Jumps After Hours - Investor's Business Daily 06.03.13 | 05:06 pm
- Stock Market Closes Higher As Indexes Erase Losses - Investor's Business Daily 06.03.13 | 04:06 pm
- Stock Market News for June 3, 2013 - Market News - Zacks 06.03.13 | 03:06 pm
